LONDON (ShareCast) - (Sharecast News) - Eli Lilly's combination antibody therapy against Covid-19 reduces the risk of death or hospitalisation by well over four fifths among high-risk patients, the results of a study showed.
Significantly, perhaps, Daniel Skovronsky, Eli Lilly's chief scientific officer, said the therapy offered greater protection against the new strains of the virus.

"We are quite confident this combo covers all of the variants in the U.S.," he reportedly said, according to Reuters.

The therapy combined two antibodies, bamlanivimab and etesevimab.

It was the second study to validate the therapy's effectiveness in treating mild to moderate cases of Covid-19.

Eli Lilly was prepared to manufacture 1.0m doses of the the therapy in the coming months.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE